.
MergerLinks Header Logo

Announced

Completed

AEON Biopharma went public via a SPAC merger with Priveterra Acquisition in a $475m deal.

Financials

Edit Data
Transaction Value£387m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Domestic

De-SPAC

Merger

biopharmaceutical company

Pharmaceuticals

drug development

Private

Reverse Takeover

Single Bidder

United States

Acquisition

Majority

Friendly

Completed

Synopsis

Edit

AEON Biopharma, a clinical-stage biopharmaceutical company, went public via a SPAC merger with Priveterra Acquisition, a blank cheque company, in a $475m deal. “We are grateful to all investors that continue to support Priveterra’s investment thesis in combining with AEON, along with their significant contributions of up to $125 million in arranged funding. I look forward to continuing my journey with AEON," Robert Palmisano, Priveterra Acquisition Chairman and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US